1. Home
  2. Stocks
  3. Vaishali Share Price

Vaishali Pharma Share Price

Trading Small Cap

₹18.75 +0.29 (1.57%)

05 Nov, 2024 17:22

SIP TrendupStart SIP in VAISHALI

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹18
  • High
  • ₹19
  • 52 Week Low
  • ₹12
  • 52 Week High
  • ₹25
  • Open Price₹19
  • Previous Close₹18
  • Volume156,468

Investment Returns

  • Over 1 Month -0.9%
  • Over 3 Month + 17.78%
  • Over 6 Month + 14.75%
  • Over 1 Year + 35.97%
SIP Lightning

Smart Investing Starts Here Start SIP with Vaishali Pharma for Steady Growth!

Vaishali Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 350.3
  • PEG Ratio
  • -4
  • Market Cap Cr
  • 292
  • P/B Ratio
  • 8.1
  • Average True Range
  • 1.29
  • EPS
  • 0.1
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.16
  • RSI
  • 46.63
  • MFI
  • 13.43

Vaishali Pharma Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations18.0832.4027.9012.5713.42
Total Income From Operations18.0832.4027.9012.5713.42
P/L Before Interest, Excpt. Items & Tax2.65-6.023.302.832.55
P/L Before Exceptional Items & Tax2.27-6.422.862.362.12
P/L After Tax from Ordinary Activities1.70-4.682.111.701.59
Net Profit/Loss For the Period1.70-4.682.111.701.59
IndicatorMar 24Mar 23
Revenue From Operations [Gross]81.7663.82
Revenue From Operations [Net]81.7663.82
Total Operating Revenues86.2869.66
Total Revenue88.3171.89
Total Expenses87.3963.05
Profit/Loss Before Tax0.938.85
Profit/Loss For The Period0.726.60
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity0.811.08
Net Cash Used In Investing Activity1.200.28
Net Cash Used in Finance Activity-1.42-1.73
Net Inc/Dec In Cash And Equivalent0.59-0.37
Cash And Equivalent End Of Year1.580.98
IndicatorMar 24Mar 23
Total Share Capital10.7210.55
Total Non-Current Liabilities4.036.30
Total Current Liabilities33.0832.07
Total Capital And Liabilities79.9678.90
Total Non-Current Assets5.446.23
Total Current Assets74.5272.67
Total Assets79.9678.90
Indicator20242023
EBIT Margin (%)3.0815.58
Return On Capital Employed (%)5.6823.17
Return On Equity (%)2.0020.02
Long Term Debt To Equity (%)10.0415.85
Book Value/Share (INR)33.4131.26
Indicator20242023
EBIT Margin (%)3.0815.58
Return On Capital Employed (%)5.6823.17
Return On Equity (%)2.0020.02
Long Term Debt To Equity (%)10.0415.85
Book Value/Share (INR)33.4131.26

Vaishali Pharma Technicals

EMA & SMA

Current Price
₹18.75
+ 0.29 (1.57%)
pointer
  • stock-down_img
  • Bullish Moving Average 10
  • stock-up_img
  • Bearish Moving Average 6
  • 20 Day
  • ₹18.97
  • 50 Day
  • ₹18.80
  • 100 Day
  • ₹17.98
  • 200 Day
  • ₹16.93

Resistance and Support

18.63 Pivot Speed
  • R3 20.91
  • R2 20.21
  • R1 19.33
  • S1 17.75
  • S2 17.05
  • S3 16.17

Is Vaishali Pharma Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vaishali Pharma has an operating revenue of Rs. 90.94 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 1% needs improvement, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 33 which is a POOR score indicating inconsistency in earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Vaishali Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-10 Others To consider other business matters split from Rs. 10/- to Rs. 2/-.
2024-08-28 Bonus issue, Stock Split & Fund Raising To consider the proposal for raising of fund by way of equity shares, debentures or other securities through rights issue, private placement, qualified institutions placement (QIP), preferential issue split from Rs. 10/- to Rs. 2/-.
2024-08-14 Quarterly Results
2024-02-02 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2024-10-15 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.
Date Purpose Remarks
2024-10-15 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 2/-

Vaishali Pharma F&O

Vaishali Pharma Shareholding Pattern

26.32%
0%
64.98%
8.7%
  • NSE Symbol
  • VAISHALI
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Atul Arvind Vasani
  • ISIN
  • INE972X01022

Vaishali Pharma FAQs

Vaishali Pharma share price is ₹18 As on 05 November, 2024 | 17:08

The Market Cap of Vaishali Pharma is ₹291.5 Cr As on 05 November, 2024 | 17:08

The P/E ratio of Vaishali Pharma is 350.3 As on 05 November, 2024 | 17:08

The PB ratio of Vaishali Pharma is 8.1 As on 05 November, 2024 | 17:08

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.